Tag : LENACAPAVIR

CONFERENCE UPDATE

Twice yearly lenacapavir demonstrates high efficacy for HIV prevention and safety in adolescents and adults: Insights from PURPOSE 1
Despite the high incidence of human immunodeficiency virus (HIV) infection among adolescents, this population has historically been excluded from phase 3 HIV trials. As a result, clinical data on new therapeutic options in adolescents often become available years after adult approvals